Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

被引：0
|
作者：
Chen, Robert W. [1 ]
Gopal, Ajay K. [2 ]
Smith, Scott E. [3 ]
Ansell, Stephen M. [4 ]
Rosenblatt, Joseph D. [5 ]
Savage, Kerry J. [6 ]
Connors, Joseph M. [7 ]
Engert, Andreas [8 ]
Larsen, Emily K. [9 ]
Sievers, Eric L. [9 ]
Younes, Anas [10 ]
机构：
[1] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA 91010 USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Med Ctr, Seattle, WA 98195 USA
[3] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Mayo Clin, Div Hematol, Rochester, MN USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[6] BC Canc Agcy Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada
[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada
[8] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[9] Seattle Genet Inc, Bothell, WA USA
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3689.3689
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3689
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin
    Faulk, Kelly E.
    Sopfe, Jenna M.
    Campbell, Kristen
    Liptzin, Deborah R.
    Liu, Arthur K.
    Franklin, Anna R. K.
    Cost, Carrye R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (02) : 251 - 256
  • [42] SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN: THE GREEK EXPERIENCE
    Tsirigotis, P.
    Vassilakopoulos, T.
    Bousiou, Z.
    Mpatsis, I.
    Gkirkas, K.
    Sakellari, I.
    Papageorgiou, S.
    Roussou, P.
    Pangalis, G.
    Galani, Z.
    Moschoyianni, M.
    Vassilopoulos, G.
    Repoussis, P.
    Megalakaki, E.
    Michalis, E.
    Anagnostopoulos, N.
    Calpadaki, C.
    Papadaki, H.
    Margaritis, D.
    Chatzimichail, E.
    Briassoulis, E.
    Spyridonidis, A.
    Grentzelias, D.
    Anargyrou, K.
    Tsionos, K.
    Mpanti, A.
    Poulakidas, E.
    Palaska, C.
    Gribabi, D.
    Apostolidis, J.
    Pappa, V.
    Harhalakis, N.
    Panayiotidis, P.
    Konstantopoulos, K.
    Anagnostopoulos, A.
    Angelopoulou, M.
    HAEMATOLOGICA, 2015, 100 : 454 - 455
  • [43] Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
    Ulu, Bahar Uncu
    Dal, Mehmet Sinan
    Hindilerden, Ipek Yonal
    Akay, Olga Meltem
    Mehtap, Ozgur
    Buyukkurt, Nurhilal
    Hindilerden, Fehmi
    Gunes, Ahmet Kursad
    Yigenoglu, Tugce Nur
    Basci, Semih
    Cakar, Merih Kizil
    Acik, Didar Yanardag
    Korkmaz, Serdal
    Ulas, Turgay
    Ozet, Gulsum
    Ferhanoglu, Burhan
    Nalcaci, Meliha
    Altuntas, Fevzi
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 190 - 198
  • [44] Is there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?
    Chen, Robert W.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (11)
  • [45] Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
    Moskowitz, Alison J.
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Brown, Lisa
    Taft, David
    Ansari, Sahar
    Zak, Daniel E.
    Sacchi, Mariana
    Manley, Thomas
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [46] Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert W.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (02) : 6 - 6
  • [47] Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Huebner, Dirk
    Fong, Abraham
    Younes, Anas
    BLOOD, 2015, 126 (23)
  • [48] Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Chen, Lu
    Herrera, Alex F.
    Mei, Matthew
    McBride, Katrina
    Abary, Rosie
    Siddiqi, Tanya
    Popplewell, Leslie
    Forman, Stephen J.
    Rosen, Steven T.
    Kwak, Larry W.
    BLOOD, 2018, 132
  • [49] Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Pro, Barbara
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandern, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Wang, Yinghui
    Huebner, Dirk
    Kennedy, Dana A.
    Shustov, Andrei R.
    BLOOD, 2014, 124 (21)
  • [50] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma
    Kaleka, Guneet
    Moskoff, Benjamin
    Zafar, Aneeqa
    Esteghamat, Naseem S.
    Abedi, Mehrdad
    Socola, Francisco Andres
    Hoeg, Rasmus T.
    Tuscano, Joseph M.
    BLOOD, 2024, 144 : 6318 - 6319
12345